title: Reduction in dose of intravitreous bevacizumab before vitrectomy for proliferative diabetic retinopathy.
authors.affiliation: Department of Ophthalmology, Kagawa University Faculty of Medicine, 1750-1 Ikenobe, Miki-cho, Kita-gun, Kagawa 761-0793, Japan. proceed@kms.ac.jp
authors.forename: Hidetaka
authors.initials: H
authors.lastname: Yamaji
authors.forename: Fumio
authors.initials: F
authors.lastname: Shiraga
authors.forename: Chieko
authors.initials: C
authors.lastname: Shiragami
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Nomoto
authors.forename: Tomoyoshi
authors.initials: T
authors.lastname: Fujita
authors.forename: Kouki
authors.initials: K
authors.lastname: Fukuda
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D001082:Aqueous Humor / Q000378:metabolism; D000068258:Bevacizumab; D003930:Diabetic Retinopathy / Q000175:diagnosis / Q000188:drug therapy*; D004797:Enzyme-Linked Immunosorbent Assay; D005451:Fluorescein Angiography; D006801:Humans; D058449:Intravitreal Injections; D008875:Middle Aged; D056687:Off-Label Use; D015861:Retinal Neovascularization / Q000175:diagnosis / Q000188:drug therapy*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors / Q000378:metabolism; D014821:Vitrectomy
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab